Musculoskeletal manifestations and autoimmune diseases related to new biologic agents
- 1 January 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 18 (1), 96-100
- https://doi.org/10.1097/01.bor.0000198007.73320.6e
Abstract
The anti-tumor necrosis factor agents are now widely used in the management of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile inflammatory arthritis. One of the most common observations made during their use is the development of autoantibodies. The purpose of this paper is to review this phenomenon and its clinical implications. While the development of different autoantibodies is a common encounter, rare cases of lupus-like syndromes have been reported. On the other hand, a variety of immune-mediated clinical manifestations have been described, including vasculitis and demyelinating syndromes. Rare cases of cytopenia and non-specific lung injuries have also been reported. While these clinical complications are rare and isolated events, clinicians must be aware of their occurrence. The experience with the anti-tumor necrosis factor agents is rather short and new, unusual immune-mediated complications may still appear. Clinicians should be prepared to recognize them.Keywords
This publication has 21 references indexed in Scilit:
- Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritisArthritis & Rheumatism, 2005
- Treatment with tumour necrosis factor antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodiesAnnals Of The Rheumatic Diseases, 2004
- Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFAnnals Of The Rheumatic Diseases, 2004
- Accumulation of plasma nucleosomes upon treatment with anti‐tumour necrosis factor‐α antibodiesJournal of Internal Medicine, 2004
- Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort studyGastroenterology, 2003
- Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathyArthritis & Rheumatism, 2003
- Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trialRheumatology, 2002
- Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open‐label studyRheumatology, 2002
- Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trialsArthritis & Rheumatism, 2000
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993